DiaMedica Therapeutics (DMAC) Stock Chart & Stock Price History → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free DMAC Stock Alerts $3.06 -0.11 (-3.47%) (As of 04:16 PM ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media DiaMedica Therapeutics Stock Price Performance5 Day Performance+1.66%1 Month Performance+28.03%3 Month Performance+4.44%6 Month Performance+23.89%Year-To-Date Performance+7.75%1 Year Performance+36.00% Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Stansberry ResearchEverybody laughed when he recommended Netflix"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. DMAC Stock Chart for Monday, May, 20, 2024 DMAC Chart by TradingView DiaMedica Therapeutics Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/17/2024$3.17$3.17$3.20$3.167,101 shs$120.33 million05/16/2024$3.01$3.17+5.32%$3.17$3.0010,098 shs$120.33 million05/15/2024$3.02$3.01-0.33%$3.11$3.0112,225 shs$114.26 million05/14/2024$3.19$3.02-5.33%$3.16$2.9924,128 shs$114.64 million05/13/2024$3.12$3.19+2.24%$3.23$3.0118,196 shs$121.09 million05/10/2024$3.25$3.12-4.00%$3.29$3.1022,567 shs$118.43 million Get the Latest News and Ratings for DMAC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/09/2024$3.47$3.25-6.34%$3.37$3.0074,346 shs$123.37 million05/08/2024$3.66$3.47-5.19%$3.63$3.02102,294 shs$131.72 million05/07/2024$3.50$3.66+4.57%$3.73$3.57142,822 shs$138.93 million05/06/2024$3.00$3.50+16.67%$3.54$3.04143,897 shs$132.86 million05/03/2024$2.63$3.00+14.07%$3.05$2.65102,677 shs$113.88 million05/02/2024$2.59$2.63+1.54%$2.63$2.5822,095 shs$99.84 million05/01/2024$2.58$2.59+0.39%$2.63$2.5035,216 shs$98.32 million04/30/2024$2.59$2.58-0.39%$2.59$2.527,590 shs$97.94 million04/29/2024$2.57$2.59+0.78%$2.60$2.548,788 shs$98.32 million04/26/2024$2.53$2.58+1.98%$2.59$2.497,764 shs$97.94 million04/25/2024$2.45$2.53+3.27%$2.55$2.496,852 shs$96.03 million04/24/2024$2.42$2.45+1.24%$2.54$2.407,871 shs$93.00 million04/23/2024$2.51$2.42-3.59%$2.56$2.415,238 shs$91.86 million04/22/2024$2.39$2.51+5.02%$2.56$2.2621,158 shs$95.28 million04/19/2024$2.49$2.39-4.02%$2.54$2.3721,009 shs$90.72 million04/18/2024$2.60$2.49-4.23%$2.61$2.4617,421 shs$94.52 million04/17/2024$2.37$2.60+9.70%$2.64$2.3940,806 shs$98.70 million04/16/2024$2.39$2.37-0.84%$2.41$2.2916,028 shs$89.97 million04/15/2024$2.43$2.39-1.65%$2.42$2.2928,638 shs$90.72 million04/12/2024$2.54$2.43-4.33%$2.57$2.4157,793 shs$92.24 million04/11/2024$2.65$2.54-4.15%$2.67$2.4038,660 shs$96.41 million04/10/2024$2.71$2.65-2.21%$2.82$2.65188,112 shs$100.59 million04/09/2024$2.78$2.71-2.52%$2.79$2.7120,712 shs$102.87 million04/08/2024$2.98$2.78-6.71%$2.90$2.7720,485 shs$105.53 million04/05/2024$2.95$2.98+1.02%$3.20$2.87118,472 shs$113.12 million04/04/2024$2.80$2.95+5.36%$2.95$2.7045,576 shs$111.98 million04/03/2024$2.73$2.80+2.56%$2.82$2.7025,725 shs$106.29 million04/02/2024$2.73$2.73$2.75$2.6716,852 shs$103.63 million04/01/2024$2.77$2.73-1.44%$2.76$2.6719,622 shs$103.63 million03/29/2024$2.77$2.77$2.81$2.7320,761 shs$105.15 million03/28/2024$2.65$2.77+4.53%$2.81$2.7320,711 shs$105.15 million03/27/2024$2.72$2.65-2.57%$2.76$2.658,461 shs$100.59 million03/26/2024$2.68$2.72+1.49%$2.82$2.6615,865 shs$103.25 million03/25/2024$2.75$2.68-2.55%$2.95$2.6820,684 shs$101.73 million**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25!Click for Zack's full report03/22/2024$2.69$2.75+2.23%$3.34$2.44314,800 shs$104.39 million03/21/2024$2.77$2.69-2.89%$2.87$2.6536,125 shs$102.09 million03/20/2024$2.82$2.77-1.77%$2.86$2.6672,197 shs$105.12 million03/19/2024$2.85$2.82-1.05%$2.92$2.7920,866 shs$107.02 million03/18/2024$3.03$2.85-5.94%$2.96$2.8536,527 shs$108.16 million03/15/2024$2.92$3.03+3.77%$3.03$2.8658,221 shs$114.99 million03/14/2024$2.90$2.92+0.69%$2.92$2.8515,755 shs$110.81 million03/13/2024$2.89$2.90+0.35%$2.95$2.8323,497 shs$110.06 million03/12/2024$2.91$2.89-0.69%$2.95$2.8528,038 shs$109.69 million03/11/2024$3.06$2.91-4.90%$3.18$2.8721,283 shs$110.43 million03/08/2024$3.07$3.06-0.33%$3.14$3.0527,946 shs$116.13 million03/07/2024$3.02$3.07+1.66%$3.10$3.048,218 shs$114.62 million03/06/2024$3.10$3.02-2.58%$3.11$3.0127,581 shs$114.61 million03/05/2024$3.20$3.10-3.13%$3.24$3.0716,676 shs$117.65 million03/04/2024$3.07$3.20+4.23%$3.27$2.9960,479 shs$121.44 million03/01/2024$3.00$3.07+2.33%$3.15$2.9520,130 shs$116.51 million02/29/2024$3.03$3.00-0.99%$3.03$2.9512,986 shs$113.85 million02/28/2024$2.97$3.03+2.02%$3.21$2.9567,295 shs$114.99 million02/27/2024$2.84$2.97+4.58%$3.08$2.8839,318 shs$112.72 million02/26/2024$2.83$2.84+0.35%$2.90$2.7927,948 shs$107.78 million02/23/2024$2.88$2.83-1.57%$2.87$2.8121,351 shs$107.40 million02/22/2024$2.90$2.88-0.86%$2.93$2.8513,965 shs$110.07 million02/21/2024$2.93$2.90-1.02%$2.94$2.8614,576 shs$110.06 million02/20/2024$2.93$2.93$3.01$2.8466,563 shs$111.19 million02/19/2024$2.93$2.93$3.01$2.9130,300 shs$111.19 million Related Companies: Coya Therapeutics Stock Price Chart Vistagen Therapeutics Stock Price Chart Nuvectis Pharma Stock Price Chart FibroGen Stock Price Chart Adagene Stock Price Chart Immunic Stock Price Chart Amylyx Pharmaceuticals Stock Price Chart Abeona Therapeutics Stock Price Chart OptiNose Stock Price Chart Rezolute Stock Price Chart Receive DMAC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:DMAC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.